Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mecasermin rinfabate.

Stephen F Kemp1

  • 1University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. KempStephenF@uams.edu

Drugs of Today (Barcelona, Spain : 1998)
|March 24, 2007
PubMed
Summary
This summary is machine-generated.

Mecasermin rinfabate, a complex of insulin-like growth factor (IGF)-I and IGFBP-3, is approved for severe IGF deficiency. It improves growth velocity and reduces hypoglycemia risk compared to unbound IGF-I.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recognition, treatment, and prevention of anaphylaxis.

Immunology and allergy clinics of North America·2015
Same author

Pediatric allergic rhinitis.

Immunology and allergy clinics of North America·2014
Same author

Pharmacotherapy in refractory anaphylaxis: when intramuscular epinephrine fails.

Current opinion in allergy and clinical immunology·2014
Same author

Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization.

The World Allergy Organization journal·2013
Same author

Growth and growth hormone treatment in children with chronic diseases.

Endocrinology and metabolism clinics of North America·2012
Same author

Emerging options in growth hormone therapy: an update.

Drug design, development and therapy·2011
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Pediatric Endocrinology
  • Pharmacology
  • Growth Hormone Therapy

Background:

  • Severe primary IGF deficiency and growth hormone gene deletion present treatment challenges.
  • Unbound recombinant human IGF-I (rhIGF-I) administration has been associated with adverse events like hypoglycemia.
  • The serum half-life of rhIGF-I is affected by binding protein concentrations, particularly in growth hormone insensitivity syndrome.

Purpose of the Study:

  • To evaluate the efficacy and safety of mecasermin rinfabate in treating severe primary IGF deficiency.
  • To assess the impact of mecasermin rinfabate on growth velocity in children.
  • To determine if mecasermin rinfabate mitigates adverse events associated with IGF-I administration.

Main Methods:

  • Mecasermin rinfabate, a complex of IGF-I and IGFBP-3, was administered to patients.

Related Experiment Videos

  • Growth velocity was monitored in children with severe primary IGF deficiency or growth hormone gene deletion.
  • Adverse events, including hypoglycemia, were recorded and compared to historical data for unbound rhIGF-I.

    • Main Results:

    • Mecasermin rinfabate has been approved for treating severe primary IGF deficiency and related conditions.
    • Administration of mecasermin rinfabate has been shown to increase growth velocity in pediatric patients.
    • The complex formulation is expected to prolong rhIGF half-life and counteract hypoglycemia.

    Conclusions:

    • Mecasermin rinfabate offers a therapeutic option for severe primary IGF deficiency.
    • The drug effectively enhances growth velocity in target pediatric populations.
    • Mecasermin rinfabate's formulation may improve the safety profile of IGF-I therapy by reducing hypoglycemia risk.